Workflow
小分子药物分离纯化装备
icon
Search documents
色谱技术供应商汉邦科技开启申购 主要客户含甘李药业等知名药企
Zhi Tong Cai Jing· 2025-05-06 22:43
Core Viewpoint - Hanbang Technology (688755.SH) has initiated its subscription with an issue price of 22.77 yuan per share and a price-to-earnings ratio of 26.35 times, focusing on chromatography technology for pharmaceutical and life sciences sectors [1] Company Overview - Hanbang Technology is a high-tech enterprise that integrates research and development, production, and sales, primarily providing separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences industries [1] - The company's products are widely used in the research and production of antibodies, recombinant proteins, vaccines, insulin, peptides, contrast agents, antibiotics, and natural products [1] Product Segmentation - The main products are categorized into small molecule drug separation and purification equipment and large molecule drug separation and purification equipment, applicable in various industrial production and laboratory research scenarios [1] - The small molecule liquid chromatography equipment is divided into laboratory instruments and production-grade equipment, with Hanbang Technology ranking second in the production-grade liquid chromatography separation equipment market in China, holding approximately 12.7% market share [4] Financial Performance - The company reported revenues of approximately 321 million yuan, 482 million yuan, and 619 million yuan for the years 2021, 2022, and 2023, respectively [6] - Net profits for the same years were approximately 4.86 million yuan, 38.56 million yuan, and 51.50 million yuan [6] Market Position - According to data from Sullivan, the total market size for liquid chromatography equipment in China exceeded 2.7 billion yuan in 2023, with Agilent holding the largest market share at 23.2% [4] - Hanbang Technology has sold its products to over 2,000 customers domestically and internationally, including well-known pharmaceutical companies such as Sitaly, Ganli Pharmaceutical, and China National Pharmaceutical Group [3] Investment Projects - The company plans to use the raised funds for projects including the annual production of 1,000 units of liquid chromatography series separation equipment, the establishment of a chromatography separation equipment R&D center, and the annual production of 2,000 laboratory chromatography separation and purification instruments [9]